BioAlliance Pharma Receives â¬6.4 Million in Funding for the Development of Its Innovative Cancer Therapeutics PARIS - (Business Wire) BioAlliance Pharma SA (Paris:BIO), the specialty Photos : Onxeo - Design : 1sur1.net, BioAlliance Pharma and Topotarget shareholders approve proposed cross-border merger to create Onxeo. A replay of the conference call will be available approximately two hours following the conference call on both Topotarget and BioAlliance Pharma’ websites. It demonstrates that it is a “meeting of similar minds” with a shared vision of creating an immediately leading orphan oncology company with a strong patient focus”. Eurofins Pharma U.S. Holdings, Inc. v. Bioalliance Pharma SA, No. The combined company will be led by Judith Greciet, Chief Executive Officer of BioAlliance Pharma, Mr. Patrick Langlois, will continue to serve as chairman of the Board of Directors of BioAlliance Pharma. About BioAlliance Pharma Created in 1997 and listed on the Euronext stock market in Paris in 2005, BioAlliance Pharma designs, develops and brings to market innovative drugs for the treatment of cancer and its associated pathologies, more specifically for severe and orphan-status diseases. Centerview Partners and Nordea acted as financial advisors to BioAlliance Pharma in connection with the merger. BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the launch of Sitavig® (acyclovir Lauriad®) in the United States by its commercial partner, Innocutis Holdings LLC, and the granting of a new U.S. Sitavig® patent by the United States Patent and Trademark Office. Judith Greciet, Chief Executive Officer of BioAlliance Pharma and Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma, will comment on this transaction specifically for the media during a conference call starting at 09:30 am CET today. | Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer ⦠The overall unmet medical need is significant and new rare (or orphan) diseases are continuously discovered, The new entity will be supported by a highly complementary pipeline of late-stage products with several significant value-creating events anticipated in both the short and medium term, and will benefit from operational efficiencies, combined knowledge-sharing, and a diversified revenue stream driving growth, Topotarget’s primary product, belinostat, is a novel pan-HDAC (histone deacetylase) inhibitor with more than 1,100 patients treated, BioAlliance Pharma has two products in late-stage development, The merger will result in a broadened shareholder base with increased market capitalization, and a strengthened value proposition for US and European based investors, The combined company will be under the leadership of an experienced management team and supervised by a highly skilled international Board of Directors with extensive pharmaceutical industry experience and proven track record, The merger agreement is endorsed by the two largest institutional shareholders of both companies – in the case of BioAlliance Pharma by Financière de la Montagne and Idinvest Partners, representing 18.8% of the share capital of BioAlliance Pharma and in the case of Topotarget by HealthCap funds and HBM Healthcare Investments, representing 12.6% of the non-diluted share capital of Topotarget – who have agreed to vote in favor of the merger proposal at the upcoming extraordinary general meetings of the respective companies, Shares issued by Topotarget will be exchanged to the effect that shareholders of Topotarget will receive 2 newly issued shares in the continuing company, BioAlliance Pharma, for 27 Topotarget shares held, resulting in shareholders of Topotarget owning approximately 1/3 of the shares in the merged company, while existing shareholders of BioAlliance Pharma will hold approximately 2/3, The merger will be structured as a tax exempt cross-border merger in accordance with Danish, French, and EU legislation, The merger proposal is, among others, subject to approval at extraordinary general meetings which are expected to be held on June 27, 2014 for Topotarget and on June 30, 2014 for BioAlliance Pharma, All equity warrants issued by Topotarget (including any warrants not yet vested) will be accelerated and thereby allow the holders of such warrants to exercise their warrants during a period to be determined shortly (those non-exercised will be forfeited), The merger is expected to be completed in July/August 2014, BioAlliance Pharma, listed on Euronext Paris, will apply for a dual listing of its shares at NASDAQ OMX Copenhagen. DUBLIN---- Research and Markets has announced the addition of Global Markets Direct's new company profile " BioAlliance Pharma SA- Product Pipeline Review- 2012" to their offering. The shareholders also approved the appointment of Orfacare Consulting GmbH, represented by Mr. Bo Jesper Hansen, and of Mr. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support To Gain a Better Understanding of the Company, its Product Portfolio and its Management Team, BioAlliance Pharma Organizes a Symposium "Oncology: Key Issues for the Future" Please note that Bo Jesper Hansen, Chairman of the Board of Directors of Topotarget and Anders Vadsholt, Chief Executive Officer of Topotarget will be available during the day to comment on this transaction for the Danish media (see below contact details), Bo Jesper Hansen, Chairman of the Board of Directors, Michael Steen-Knudsen – Impact Communications, 49, avenue du Général Martial Valin BioAlliance Pharma SA announced preliminary phase I clinical results with its AMEP® biotherapy developed in advanced or metastatic ⦠The conference call will be held in French. Under the terms of the merger agreement, BioAlliance Pharma will be the continuing company and shares issued by Topotarget will be exchanged to the effect that shareholders of Topotarget will receive 2 newly issued shares in BioAlliance Pharma for each 27 Topotarget shares held, resulting in shareholders of Topotarget owning approximately 1/3 of the shares in the merged company, while ⦠BioAlliance Pharmaâs shares (including the newly issued shares) will remain admitted to trading on Euronext Paris under the name Onxeo (ticker: ONXEO). Mbt is a Trademark by Bioalliance Pharma, the address on file for this trademark is 49 Boulevard Du General Martial Valin, Paris 75015 As previously announced, Judith Greciet will be the CEO of Onxeo and Patrick Langlois the Chairman of the Board of Directors. 75015 PARIS â FRANCE To participate in the conference call, you may call the following telephone number, 5 minutes prior to the scheduled start time. Sept. 18, 2009). Marktanalyse - BioAlliance Pharma SA - Product Pipeline Review - 2014 BioAlliance Pharma. 212 articles with BioAlliance Pharma. BioAlliance Pharma announces positive preliminary phase I clinical results with its AMEP biotherapy for metastatic melanoma. BioAlliance Pharma (Paris:BIO) was informed that a civil action was filed in Delaware by Eurofins Pharma US Holding Inc. and one of its affiliates Viralliance Inc. (« Eurofins ») against BioAlliance Pharma and one of its executives. BioAlliance Pharma SA (Euronext Paris - BIO), an innovative company specializing in the development of drugs for orphan oncology diseases, and Topotarget A/S (NASDAQ OMX - TOPO), a Danish based biopharmaceutical company focusing on late-stage clinical development for orphan oncology, today announce that the shareholders of both companies have approved all resolutions with more than 99% voting in favor of the proposed cross-border merger between BioAlliance Pharma SA and Topotarget A/S on 27 June 2014 and 30 June 2014. 75015 PARIS – FRANCE Specifically, the Court held that the claims against BioAlliance Group and Avenard should be dismissed for lack of personal jurisdiction, and that the action should be dismissed under the doctrine of forum non conveniens. The call will be held in English. 140630_ Approval of the Merger by the Shareholders EN, 49, avenue du Général Martial Valin Any decision to participate in the merger should be based on the full documentation, including a registered prospectus (Document E) and a merger plan, to be published ahead of the general meetings. BioAlliance Pharma is a French drug- development company focused on orphan cancer and supportive care treatments. Bioz Stars score: 88/100, based on 3 PubMed citations. 4. BioAlliance Pharma SA, an innovative company specialized in the development of drugs within orphan oncology diseases, and Topotarget A/S, a Scandinavian-based biopharmaceutical company, announced their intention to merge to create a leading orphan oncology company with a highly complementary pipelines of late-stage products addressing significant unmet medical needs. Onxeo is a Trademark by Bioalliance Pharma, the address on file for this trademark is 49 Boulevard Du Général Martial Valin, Paris 75015 BioAlliance Pharma and Topotarget shareholders approve proposed cross-border merger to create Onxeo Announcement no. o The compound has potential for being explored into other rare cancer indications within hematology and solid tumors. We are confident that this merger will deliver to our shareholders the best possible value and the opportunity to jointly shape a dynamic new player in the orphan oncology market.”, Management and Corporate Governance following completion of the merger, - Meeting of the Boards of Directors to approve final merger documentation, following exercise of Topotarget warrants, - Press release / company announcement on final terms of the merger, - Filing of final merger plan with French and Danish authorities (post-exercise period of the Topotarget equity warrants), - Clearance statement (enregistrement) on merger prospectus (Document E) from French regulator and passport of merger prospectus to Denmark, - Calling for the Extraordinary General Meetings, - Extraordinary General Meeting of Topotarget to approve merger, - Extraordinary General Meeting of BioAlliance to approve merger. BioAlliance Pharma SA announced preliminary phase I clinical results with its AMEP® biotherapy developed in advanced or metastatic ⦠Back Bay Life Science Advisors, acted as scientific advisor to Topotarget. o Belinostat is in a pre-registration phase with the FDA for the treatment of relapsed or refractory PTCL (peripheral T-cell lymphoma). Reads . It is a unique and timely opportunity to develop an orphan oncology portfolio, which addresses a wider range of life-threatening medical conditions, while creating value for our shareholders”. Altana and Bech Bruun acted as legal counsel to BioAlliance Pharma. Onxeo designs and develops novel oncology drugs targeting tumor DNA repair functions. Topotarget is managed by a highly-experienced team of executives, and the merger will enable both teams to combine their respective expertise to create a new company with a robust and innovative pipeline that is primed for success. Following approval of the merger by the companiesâ shareholders, the completion of the merger is now subject to registration by the relevant French and Danish authorities, which is expected to occur in the course of July 2014. BioAlliance Pharma has established several strategic alliances for commercializing Loramyc®, with agreements in 2007 for Europe (with the SpeBio joint venture) and the United States (with Par Pharmaceutical) and in 2008 for Asia (Korea, Malaysia, Singapore and Taiwan with Handok Pharmaceuticals and then China with Novamed). Contact. Judith Greciet, Chief Executive Officer of BioAlliance Pharma and Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma, jointly with Anders Vadsholt, Chief Executive Officer of Topotarget and Bo Jesper Hansen, Chairman of the Board of Directors of Topotarget will comment on this merger and will be available for a webcast to answer questions during a conference call starting today at 10.30 am CET. The expected last day of trading of TopoTarget on NASDAQ OMX Copenhagen and expected first day of trading of BioAlliance (renamed Onxeo) on NASDAQ OMX Copenhagen will be announced in due course. PARIS, FRANCE AND COPENHAGEN, DENMARK – April 16, 2014 – BioAlliance Pharma SA (Euronext Paris - BIO), an innovative company specialized in the development of drugs within orphan oncology diseases, and Topotarget A/S (NASDAQ OMX - TOPO) a Scandinavian-based biopharmaceutical company, today announced their intention to merge to create a leading orphan oncology company with a highly complementary pipelines of late-stage products addressing significant unmet medical needs. This transaction will result in a new and true leader in orphan oncology. About. 2010 Decisions Opinions of the United States Court of Appeals for the Third Circuit 10-12-2010 Eurofins Pharma US Holdings v. BIoAlliance Pharma SA Photos : Onxeo - Design : 1sur1.net, BioAlliance Pharma and Topotarget enter into merger agreement to create a leading orphan oncology company, The merger of the two biopharmaceutical companies creates a leading orphan oncology company with a highly complementary pipeline of late-stage targeting genuine unmet medical needs, The total market for orphan oncology drugs exceeds USD ~45 billion in 2013 and is expected to reach USD ~80 billion in 2018. 13-14 Page 2 of 3 For further information, please contact: BioAlliance Pharma: Judith Greciet, Chief Executive Officer +33 1 45 58 76 00 Caroline Carmagnol - AlizéeRP +33 6 64 18 99 59 Topotarget: PARIS--(BUSINESS WIRE)--Regulatory News: Bioalliance Pharma SA ⦠Onxeo is a clinical-stage biotechnology company developing novel oncology drugs targeting tumor DNA-binding functions. Topotarget holds the exclusive rights outside North America and India. Further details on the merger features and terms thereof will be given on or about the time of the calling for the extraordinary general meetings expected on May 26, 2014. Network. Success of the First BioAlliance Pharmaâs Symposium Oncology: Key Issues for the Future. With the Topotarget merger to create Onxeo, it has three late- stage orphan oncology assets it could commercialise alone. Assignee: BioAlliance Pharma SA Inventors: Pierre Attali, Dominique Costantini, Caroline Lemarchand PROLONGED RELEASE BIOADHESIVE THERAPEUTIC ⦠The merger agreement has been unanimously approved by the Boards of Directors of both companies. It has two FDA-approved specialty products . With a portfolio of advanced programs targeting severe orphan oncology diseases for which there is an unmet medical need, Onxeo will offer increased market attractiveness, notably towards specialized international investors, using its scale and significant footprint as a biotechnology leader with a growing portfolio of high value-added products. EY and Grant Thornton acted as BioAlliance Pharma’s advisors on auditing and accounting aspects, and Arsene Taxand and Bech-Bruun acted as advisors on tax aspects. BioAlliance Pharma bioalliance pharma encapsulates doxorubicin Bioalliance Pharma Encapsulates Doxorubicin, supplied by BioAlliance Pharma, used in various techniques. I am confident that, under the leadership of Judith Greciet, the new entity will unleash its full potential and create value for our shareholders.”.
Global Placement and Open Price Offer
IPO price. The combined entity aims to become a leading orphan oncology company and will be renamed Onxeo upon completion of the merger. -- Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical needs --, -- Topotarget shareholders will receive 2 new BioAlliance Pharma ordinary shares for every 27 Topotarget shares that they own, which implies approximately a 1/3 ownership for Topotarget shareholders and approximately a 2/3 ownership for BioAlliance Pharma shareholders --, -- BioAlliance Pharma is listed on Euronext Paris and application will be made for a dual listing on NASDAQ OMX Copenhagen --.Ex Kam Nach Jahren Zurück, Is Levi Ackerman French, Brut- Und Setzzeit Niedersachsen 2020 Baumfällung, Best Race For Paladin 5e, Atlas Submarine Cheat, Logineo Messenger Einrichten, Hss Bohrer Unterschiede, Zahnarzt Niendorf Nord, Bauchschmerzen Baby Abends, Magersucht Essensplan Klinik,